Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Torsten Haferlach

Showing results (201-210 of 596) with videos related to

Pageof 60
Sort By:
Blood Advances|September 27, 2021
Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignanciesAnna Stengel, Constance Baer, Wencke Walter, et al.
Cytometry. Part B, Clinical Cytometry|January 28, 2022
Identification of a specific immunophenotype associated with a consistent pattern of genetic mutations including SRFS2 and gene expression profile in MDSElisabeth Weiß, Wencke Walter, Manja Meggendorfer, et al.
Bioinformatics (Oxford, England)|February 26, 2011
R453Plus1Toolbox: an R/Bioconductor package for analyzing Roche 454 Sequencing dataHans-Ulrich Klein, Christoph Bartenhagen, Alexander Kohlmann, et al.
European Journal of Haematology|July 17, 2019
Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population-based studyMichael Lauseker, Roman Gerlach, Wenke Worseg, et al.
Blood|October 29, 2005
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survivalSusanne Schnittger, Tobias M Kohl, Torsten Haferlach, et al.
Leukemia|March 24, 2018
IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategiesManja Meggendorfer, Luca Vincenzo Cappelli, Wencke Walter, et al.
BMC Bioinformatics|December 17, 2009
Quantitative comparison of microarray experiments with published leukemia related gene expression signaturesHans-Ulrich Klein, Christian Ruckert, Alexander Kohlmann, et al.
Leukemia Research|November 11, 2011
Older patients with normal karyotype acute myeloid leukemia have a higher rate of genomic changes compared to young patients as determined by SNP array analysisMaya Koren-Michowitz, Aiko Sato-Otsubo, Arnon Nagler, et al.
Advances in Hematology|November 24, 2011
Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemiaAnthony Oyekunle, Torsten Haferlach, Nicolaus Kröger, et al.
Leukemia|July 4, 2024
Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutationPhilipp Ernst, Jenny Rinke, Georg-Nikolaus Franke, et al.
Pageof 60

Showing results (201-210 of 596) with videos related to

Sort By:
Pageof 60
Blood Advances|September 27, 2021
Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignanciesAnna Stengel, Constance Baer, Wencke Walter, et al.
Cytometry. Part B, Clinical Cytometry|January 28, 2022
Identification of a specific immunophenotype associated with a consistent pattern of genetic mutations including SRFS2 and gene expression profile in MDSElisabeth Weiß, Wencke Walter, Manja Meggendorfer, et al.
Bioinformatics (Oxford, England)|February 26, 2011
R453Plus1Toolbox: an R/Bioconductor package for analyzing Roche 454 Sequencing dataHans-Ulrich Klein, Christoph Bartenhagen, Alexander Kohlmann, et al.
European Journal of Haematology|July 17, 2019
Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: Results from a population-based studyMichael Lauseker, Roman Gerlach, Wenke Worseg, et al.
Blood|October 29, 2005
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survivalSusanne Schnittger, Tobias M Kohl, Torsten Haferlach, et al.
Leukemia|March 24, 2018
IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategiesManja Meggendorfer, Luca Vincenzo Cappelli, Wencke Walter, et al.
BMC Bioinformatics|December 17, 2009
Quantitative comparison of microarray experiments with published leukemia related gene expression signaturesHans-Ulrich Klein, Christian Ruckert, Alexander Kohlmann, et al.
Leukemia Research|November 11, 2011
Older patients with normal karyotype acute myeloid leukemia have a higher rate of genomic changes compared to young patients as determined by SNP array analysisMaya Koren-Michowitz, Aiko Sato-Otsubo, Arnon Nagler, et al.
Advances in Hematology|November 24, 2011
Molecular diagnostics, targeted therapy, and the indication for allogeneic stem cell transplantation in acute lymphoblastic leukemiaAnthony Oyekunle, Torsten Haferlach, Nicolaus Kröger, et al.
Leukemia|July 4, 2024
Treatment-free remission after third-line therapy with asciminib in chronic myeloid leukemia with an atypical e19a2 BCR::ABL1 transcript and T315I mutationPhilipp Ernst, Jenny Rinke, Georg-Nikolaus Franke, et al.
Pageof 60